API
< Back to all clusters
[BUSINESS] · India · 25 sources

started · updated

India NPPA revises prices for 543 anti-cancer drug brands

The National Pharmaceutical Pricing Authority (NPPA) has released revised maximum retail prices (MRPs) for 543 brands of anti-cancer medicines, effective November 9, 2026. This move follows a trade margin rationalisation initiative that capped margins on 137 non-scheduled anti-cancer drugs at 30 per cent of the MRP.

Some formulations are set to see dramatic price reductions of up to 93.3 per cent. Notable examples include the thiotepa vial Samtepa, which dropped from Rs 80,071.86 to Rs 7,150.33, and the palbociclib brand Palbopro, which saw a reduction from Rs 40,421.33 to Rs 2,720. The government estimates these changes could save patients approximately Rs 2,500 crore annually.

However, the price revisions do not apply to all oncology treatments. Several high-value patented drugs, including the immunotherapy medicine Keytruda (pembrolizumab) and the breast cancer drug ribociclib, remain at their previous prices. Experts noted that trade margin caps may not affect patented medicines in the absence of competition.

The announcement comes amid scrutiny from the Supreme Court of India, which recently questioned the vast disparity between manufacturer costs and patient billing, describing certain mark-ups as “loot” and “dacoity.” The Court has reserved its verdict on petitions seeking stricter price controls and mandatory generic prescriptions.

Entities

Aishwarya Bhati · Department of Pharmaceuticals · Government of India · India · Ministry of Chemicals and Fertilizers · National Pharmaceutical Pricing Authority · Sandeep Mehta · Supreme Court of India · Vikram Nath

Claims

What the coverage asserts, and how many sources carry each claim.

Sources